Oxytocin Acetate Research Peptide

In 1906 the British pharmacologist Henry Dale found that extracts of the posterior pituitary made uterine muscle contract,, and within a few years the same extracts were linked to milk let-down. The name comes from Greek words meaning “swift birth”. In the early 1950s Vincent du Vigneaud’s laboratory worked out its sequence and then, in 1953, assembled it from individual amino acids. It was the first chemical synthesis of a peptide hormone, and in 1955 du Vigneaud received the Nobel Prize in Chemistry for his work on biochemically important sulphur compounds, especially that first synthesis of a polypeptide hormone.

The sulphur explains the shape. The cysteines at positions 1 and 6 are joined by a disulphide bridge, closing the first six residues into a ring, while proline, leucine and a C-terminal glycinamide hang off it as a short tail.

Oxytocin has a close sibling in arginine vasopressin, the hormone best known for its role in water balance. Both are cyclic nonapeptides built on the same disulphide ring, and they differ at only two positions: isoleucine at position 3 of oxytocin is phenylalanine in vasopressin, and leucine at position 8 is arginine. Their genes sit side by side on human chromosome 20, the legacy of an ancient gene duplication.

That near-identical chemistry matters at the bench. Four receptors respond to this peptide family: the oxytocin receptor plus the vasopressin V1a, V1b and V2 receptors. At high concentrations oxytocin can activate V1a receptors, so well-designed studies lean on selective antagonists or receptor-knockout tissue to show which receptor is responsible for an effect.

The human oxytocin receptor was cloned in 1992 by Kimura and colleagues, who described a 388-amino-acid protein with seven membrane-spanning segments, the signature of a G protein-coupled receptor. Its main signalling route runs through Gq proteins and phospholipase C to a rise in intracellular calcium, which is why uterine smooth muscle and the milk-ejecting myoepithelial cells of the mammary gland respond so strongly. Receptor messenger RNA in uterine muscle was found to rise sharply near term.

This uterine biology explains oxytocin’s long clinical record. Oxytocin is a licensed hospital medicine, marketed under names such as Syntocinon in the UK and Pitocin in the US, used to induce or strengthen labour and to control bleeding after delivery. The receptor is targeted in the opposite direction too: atosiban, an oxytocin-receptor antagonist, has been authorised in the EU since 2000 as Tractocile for delaying threatened preterm birth.

Few animals have shaped oxytocin research like the prairie vole, a small North American rodent that forms lasting pair bonds. In 1994 Williams, Insel and colleagues reported that delivering oxytocin into the brains of female prairie voles helped them form a partner preference after a short period of cohabitation, and that a selective oxytocin-receptor antagonist blocked the effect. Compared with the montane vole, which does not pair-bond, prairie voles carry higher densities of oxytocin receptors in the nucleus accumbens, a reward-related brain region.

Mouse genetics added further layers. Mice lacking the oxytocin gene mated and gave birth normally, yet their pups could not obtain milk, establishing the hormone as essential for milk ejection. Male knockouts also failed to recognise mice they had already met, despite a normal sense of smell, a “social amnesia” that oxytocin reversed. Then a study published in Neuron complicated the story: prairie voles with the receptor gene knocked out still formed pair bonds and cared for their young, suggesting the underlying circuitry is more robust and redundant than the drug studies had implied.

Human oxytocin research accelerated after a 2005 paper in Nature reported that volunteers given intranasal oxytocin entrusted more money to a stranger in an economic “trust game”. It helped launch a large literature of nasal-spray studies on social perception and cooperation. A critical review by Nave, Camerer and McCullough pooled seven trust-game studies with 481 participants and found a combined effect that was small and not reliably different from zero. A large pre-registered replication led by Declerck and Fehr, published in Nature Human Behaviour, then found no effect of oxytocin on trusting behaviour in the original design.

Debate also continues over how much nasally applied peptide reaches the brain, so headline behavioural claims are best weighed against well-powered, pre-registered and independently replicated work.